TenNor’s article “Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections” published recently in the Journal of Medicinal Chemistry has been selected as ACS Editors’ Choice.

“Under ACS Editors' Choice, your article has been sponsored for immediate open access by ACS due to its potential for broad public interest, an honor given to one article each day of the year”, said ACS Editors.

Please use this link for free access to the article:http://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00485.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com